MannKind 
Welcome,         Profile    Billing    Logout  
 5 Products   98 Diseases   5 Products   8 Trials   722 News 


«1234»
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    SAFETY AND PHARMACOKINETICS OF TECHNOSPHERE INSULIN IN PEDIATRIC PATIENTS (E-Poster Area) -  Dec 29, 2019 - Abstract #ATTD2020ATTD_621;    
    P2
    Two patients discontinued because of adverse events (cough, diabetic ketoacidosis). Conclusions These data will help determine the appropriate age range for inclusion and recommended dosing for part 2, which will be a 1-year efficacy and safety study.
  • ||||||||||  NovoLog (insulin aspart) / Novo Nordisk, Afrezza (recombinant human insulin inhalation) / MannKind
    TECHNOSPHERE INSULIN PROVIDES BETTER EARLY POSTPRANDIAL GLUCOSE CONTROL THAN SUBCUTANEOUS RAPID-ACTING ANALOGUE (Berlin) -  Dec 29, 2019 - Abstract #ATTD2020ATTD_295;    
    P3, P4
    Conclusions The TI PPGE curves confirm TI has an earlier onset and shorter duration of action, whereas the insulin aspart PPGE curves tend to drop below baseline in the late postprandial period, reflecting a longer duration of action. The timing of hypoglycemia (levels 1 and 2) follows the pattern of PPGEs.
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    AFREZZA PRE-MEAL BOLUS REDUCES EARLY GLYCEMIC EXCURSION DURING HYBRID CLOSED LOOP TREATMENT (Berlin) -  Dec 29, 2019 - Abstract #ATTD2020ATTD_293;    
    Afrezza (AH) pre-meal bolus reduced the early glycemic excursion and improved PPG during HCL compared to RAI pre-meal bolus. The improvement in PPG has not been sustained after the end of Afrezza glucodynamic action at 120m.
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Afrezza – How to use it and when (Paris) -  Dec 29, 2019 - Abstract #ATTD2020ATTD_255;    
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Afrezza (Twitter) -  Dec 7, 2019   
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk
    Speaker (Auditorium) -  Oct 2, 2019 - Abstract #IDF2019IDF_497;    
    Newer inhaled insulin Afrezza based on a technosphere platform contains recombinant human insulin administered via a small thumb-sized device introduced in 2014 with modification in the size of the device...Other different ways of administration of insulin which can bypass hepatic first-pass metabolism are in a different phase of trial like buccal insulin, nasal insulin, ocular insulin; rectal insulin (bypasses the more proximal areas that are actively involved indigestion)...It then deploys milliposts fabricated from active pharmaceutical ingredients directly through the gastric mucosa while avoiding perforation. The preclinical study result has shown that SOMA has released the same plasma level of insulin compare to subcutaneous Learning Objectives History and development of insulinCurrent insulin therapy and delivery devices Future of insulin and its administration techniques
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    AFREZZA-INDUCED PULMONARY INFILTRATE (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 4) -  Sep 25, 2019 - Abstract #CHEST2019CHEST_1465;    
    To the best of our knowledge, this is the first known case of pulmonary infiltrate secondary to Afrezza, that resolved after discontinuing the therapy. Larger studies are required for standardizing the administration and surveillance strategies for Afrezza, so that it may serve as a model for channeling other parenteral medications in future.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
    Journal:  Insulins for type 2 diabetes. (Pubmed Central) -  Aug 6, 2019   
    Larger studies are required for standardizing the administration and surveillance strategies for Afrezza, so that it may serve as a model for channeling other parenteral medications in future. No abstract available
  • ||||||||||  Generex Oral-lyn (insulin buccal spray) / Generex, Dong Sung Pharma, Shreya Life Sciences, Afrezza (recombinant human insulin inhalation) / MannKind
    Clinical, Review, Journal:  A review of non-invasive insulin delivery systems for diabetes therapy in clinical trials over the past decade. (Pubmed Central) -  Aug 3, 2019   
    To increase patient compliance, products are slowly reaching the market that are more patient friendly, such as the insulin patch-pump systems, including Omnipod and V-Go, but also the inhaled-insulin Afrezza and the buccal insulin Oral-lyn™. In this review, we outline the history of insulin, the various options that are currently available in practice for insulin delivery, and the non-invasive delivery systems that have entered the different stages of clinical trials over the past decade.
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    #Afrezza (Twitter) -  Jun 7, 2019   
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
    Review, Journal:  Premix insulins in type 1 diabetes: the coming of degludec/aspart. (Pubmed Central) -  Apr 5, 2019   
    There may still be a role for this premixed fixed ratio formulation in patients who have opted to use Technosphere inhaled insulin prior to and post meals. In such patients, the use of a single injection of Degludec-Aspart prior to the largest meal of the day might provide an anchor to allow patients to then self-administer multiple inhalations around mealtimes.
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Trial completion date, Trial primary completion date:  Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients (clinicaltrials.gov) -  Mar 13, 2019   
    P3,  N=40, Recruiting, 
    In such patients, the use of a single injection of Degludec-Aspart prior to the largest meal of the day might provide an anchor to allow patients to then self-administer multiple inhalations around mealtimes. Trial completion date: Sep 2018 --> Sep 2020 | Trial primary completion date: Sep 2018 --> Sep 2020
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Trial completion date, Trial primary completion date:  A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone (clinicaltrials.gov) -  Feb 13, 2018   
    P4,  N=400, Recruiting, 
    Trial completion date: Apr 2018 --> Sep 2018 | Trial primary completion date: Apr 2018 --> Sep 2018 Trial primary completion date: Feb 2018 --> Sep 2018 | Trial completion date: Feb 2019 --> Sep 2019
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Enrollment open:  Afrezza Safety and Pharmacokinetics Study in Pediatric Patients (clinicaltrials.gov) -  Sep 29, 2017   
    P2,  N=46, Recruiting, 
    Initiation date: Jul 2017 --> Nov 2017 Not yet recruiting --> Recruiting
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Review, Journal:  Making Insulin Accessible: Does Inhaled Insulin Fill an Unmet Need? (Pubmed Central) -  Sep 14, 2017   
    Inhaled Technosphere(®) Insulin (TI; Afrezza(®); MannKind Corporation) was approved in 2014 for use as prandial insulin in people with diabetes...Writing and editorial support in the preparation of this publication was funded by Sanofi US, Inc., Bridgewater, New Jersey, USA. Funding for the article processing charges for this publication was provided by MannKind Corporation.